TrialThe lancet. Diabetes & endocrinology2021

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.

Mikhail N Kosiborod et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.